Ascendis Pharma Growth Disorders A/s
Clinical trials sponsored by Ascendis Pharma Growth Disorders A/s, explained in plain language.
-
New drug combo aims to boost growth in kids with dwarfism
Disease control OngoingThis study tests whether giving two weekly injections together can improve growth in children with achondroplasia, a common form of dwarfism. About 22 children aged 2 to 11 will receive the combination for up to 156 weeks. The goal is to see if the drugs work better together than…
Phase: PHASE2 • Sponsor: Ascendis Pharma Growth Disorders A/S • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Weekly shot shows promise for helping kids with dwarfism grow
Disease control ENROLLING_BY_INVITATIONThis study tests a once-weekly injection called TransCon CNP in children and teens with achondroplasia, the most common form of dwarfism. The goal is to see if it is safe and helps improve growth over several years. Participants who were in a previous TransCon CNP trial can join,…
Phase: PHASE2, PHASE3 • Sponsor: Ascendis Pharma Growth Disorders A/S • Aim: Disease control
Last updated May 06, 2026 16:02 UTC